| P-P factor | Pellagra Preventive factor = Vitamin G |
|---|---|
| ACPM | American College of Preventive Medicine |
| DPM | Diploma in Psychological Medicine; discontinue previous medication; Doctor of Physical Medicine; Doc... |
| FACPM | Fellow of the American College of Preventive Medicine |
| GPM | general preventive medicine; giant pigmented melanosome |
| myelin basic protein | <protein> Major component of the myelin sheath in mammalian CNS. Used as an antigen will induce a allergic encephalitis, possibly a model for some neurodegenerative disorders. (18 Nov 1997) |
|---|---|
| myelin basic protein kinase | <enzyme> Protein from pig brain activates ATP-mg-dependent protein phosphatase; a protein tau kinase; a multisubstrate kinase; in texts written as f subscript a Registry number: EC 2.7.1.- Synonym: protein phosphatase activator fa, glycogen synthase kinase 3, protein kinase f(a), gsk-3, gsk-3alpha, kinase f(a), gsk-3beta, mds1 gene product, p63(samk), src-activated mbp kinase, p63(mapk) (26 Jun 1999) |
| myelin basic proteins | A group of 7 proteins produced from a single gene by alternate splicing found in central and peripheral nervous system myelin. The major basic protein (mbp) has long been of interest because it is the antigen, that, when injected into an animal, elicits a cellular immune response that produces the CNS autoimmune disease called experimental allergic encephalomyelitis (encephalomyelitis, allergic). In the peripheral nervous system, myelin basic protein 18.5 kD is often referred to as the p1 protein. (12 Dec 1998) |
| haematoxylin-malachite green-basic fuchsin stain | <technique> A stain for epoxy resin-extracted sections; semi-thick sections have their plastic dissolved out and the residual tissue is stained sequentially with the various dyes; nuclei and astrocytes are purplish-pink and myelin, lipid droplets, nucleoli, and oligodendrocytes are bright blue-green. (05 Mar 2000) |
| fibroblast growth factor, basic | A single-chain polypeptide of approximately 15-16 kD which has been isolated from a variety of cells. It has a 55% amino acid residue identity to acidic fibroblast growth factor and has potent heparin-binding activity. However, in contrast to the acidic fibroblast growth factor, heparin does not potentiate the biological activities of bfgf. The growth factor is an extremely potent inducer of DNA synthesis in a variety of normal diploid mammalian cell types from mesoderm and neuroectoderm lineages and promotes cellular differentiation in vitro. (12 Dec 1998) |
| administration, oral | The giving of drugs, chemicals, or other substances by mouth. (12 Dec 1998) |
| cancer, oral | Cancer of the mouth area. A sore in the mouth that does not heal can be a warning sign of oral cancer. A biopsy is the only to know whether as abnormal area in the oral cavity is cancer. Oral cancer is caused by tobacco (smoking and chewing) and alcohol use. Surgery to remove the tumour in the mouth is the usual treatment for patients with oral cancer. (12 Dec 1998) |
| candidiasis, oral | Infection of the mucous membranes of the mouth by a fungus of the genus candida. (12 Dec 1998) |
| canine oral papilloma | Warts affecting mucous membranes of young dogs; caused by a papillomavirus. (05 Mar 2000) |
| magnesia and alumina oral suspension | A mixture of magnesium hydroxide and variable amounts of aluminum oxide; used as an antacid. (05 Mar 2000) |
| pathology, oral | A dental specialty concerned with pathology of the oral cavity. (12 Dec 1998) |
| pharyngo-oral | Relating to the pharynx and the mouth; oropharyngeal. Origin: pharyngo-+ L. Os (or-), mouth (05 Mar 2000) |
| combination oral contraceptive | A mixture of a steroid having progestational activity and an oestrogen. (05 Mar 2000) |
| contraceptives, oral | Compounds, usually hormonal, taken orally in order to block ovulation and prevent the occurrence of pregnancy. The hormones are generally oestrogen or progesterone or both. (12 Dec 1998) |
| contraceptives, oral, combined | Fixed drug combinations administered orally for contraceptive purposes. (12 Dec 1998) |